Form 4: Edwards Lifesciences CEO Sells Shares Under 10b5-1 Plan

Edwards Lifesciences CEO Bernard J. Zovighian reported transactions involving the sale of company stock under a pre-arranged trading plan.

Summary

• Bernard J. Zovighian, CEO of Edwards Lifesciences Corp (EW), reported several transactions on May 11-12, 2026.
• These transactions include the vesting of 47,207 shares of Common Stock, which were then sold for $0.0000, with the reporting person retaining beneficial ownership of 157,491.6499 shares directly.
• Additionally, 26,198 shares were sold at a weighted average price of $79.96, and 26,640 shares were disposed of at a weighted average price of $0.0000.
• Further disposals of 845 shares at a weighted average price of $78.4027 and 35,506 shares at a weighted average price of $77.9238 were also reported.
• The reporting person also holds 3,733.5603 shares indirectly through a 401(k) plan.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on December 12, 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the significant sale of shares by the CEO, despite being executed under a compliant trading plan.

Positives

• The CEO's sale of shares was conducted under a Rule 10b5-1 trading plan, which is designed to comply with insider trading regulations.
• The vesting of performance-based restricted stock units indicates that performance targets were met, as 167.70% of the target number of shares vested.
• The reporting person continues to hold a significant number of shares, indicating ongoing commitment to the company.

Negatives

• A substantial number of shares were sold by the CEO, potentially signaling a lack of confidence or a need for personal liquidity.
• The weighted average sale prices for the disposed shares were below the initial grant value or potential market price at the time of vesting.

Risks

• The sale of a large number of shares by a key executive could be interpreted negatively by the market, potentially impacting the stock price.
• The Rule 10b5-1 plan, while compliant, involves the sale of securities, which inherently reduces the reporting person's direct stake in the company.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Industry Context

StockSavvy.ai notes that insider sales, especially by CEOs, are common under Rule 10b5-1 plans, which allow executives to diversify their holdings or meet financial obligations while adhering to insider trading regulations. The volume and timing of such sales can still influence market perception.

Stakeholder Impact

• Shareholders may view the CEO's stock sales with caution, potentially leading to short-term price pressure.
• Employees may interpret the sales as a signal from leadership, though the Rule 10b5-1 plan mitigates concerns about illegal insider trading.

Next Steps

• The reporting person will continue to hold beneficial ownership of remaining shares.
• The Rule 10b5-1 plan may continue to execute transactions as per its terms.

Key Dates

Recommendation

The filing reports routine insider transactions under a pre-established plan, which is not typically a strong indicator for a buy or sell decision. While the sale of shares by the CEO warrants attention, it is executed within regulatory guidelines and does not provide sufficient negative or positive fundamental information to warrant a strong recommendation.

Keywords

Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Edwards Lifesciences, Bernard J. Zovighian, CEO, Restricted Stock Units, Vesting, Beneficial Ownership